The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis
| Autor: | Rui Min, Hongqiu Pan, Hong Shen, Jianzhong Dai, Li Zhang, Xia Zhang, Weiping Xie, Hongtao Xu, Qi Tan, Hong Wang |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Interleukin 2
Chemotherapy Tuberculosis business.industry medicine.medical_treatment General Medicine Disease Immunotherapy Pharmacology multidrug-resistant tuberculosis medicine.disease Recombinant Human Interleukin-2 law.invention Multiple drug resistance Clinical Research law CD4+CD25+ T cells medicine Recombinant DNA interleukin-2 immunotherapy business medicine.drug |
| Zdroj: | Archives of Medical Science : AMS |
| ISSN: | 1734-1922 |
| Popis: | Introduction Multidrug-resistant tuberculosis (MDR-TB) is a hard-to-treat disease with a poor outcome of chemotherapy. In the present study, the efficacy and safety of recombinant human interleukin-2 (rhIL-2) were investigated in patients with MDR-TB. Material and methods Fifty culture-confirmed patients with MDR-TB were included. Twenty-five patients were randomly assigned to the trial group (injection of 500 000 IU of rhIL-2 once every other day at the first, third, fifth and seventh months in addition to standard multidrug therapy) and another 25 patients to the control group with standard multidrug therapy. All patients were monitored clinically, and T-cell subsets were analyzed by flow cytometry. Results The rates of sputum negative conversion and X-ray resolution in the trial group were higher than those of the control, and the improvements were significant by completion of treatment. In addition, CD4+CD25+ T cells in the controls rose gradually during treatment. The levels at the end of the seventh month were significantly higher than before, which were also significantly different when compared with those from the trial group at the same time. However, there were no such changes associated with treatment in the trial group. No significant differences appeared in other T cell subsets. Conclusions Exogenous IL-2 in the present regimen improves immunity status. Adjunctive immunotherapy with a long period of rhIL-2 is a promising treatment modality for MDR-TB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|